Skip to main content
Premium Trial:

Request an Annual Quote

BioNanomatrix Raises $23.3M in Series B Round

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – BioNanomatrix today said it has closed a $23.3 million Series B financing round.

Leading the round was Domain Associates. New investor Gund Investment and existing investors Battelle Ventures, Innovation Valley Partners, and KT Venture Group also participated.

In November, the Philadelphia-based company introduced its nanoAnalyzer 1000 System, a silicon-chip based platform for single-molecule genome analysis. The system uses nanochannels in a massively parallel array format to trap individual DNA fragments, image them, and release them before the next DNA fragment flows into the channel.

Since its introduction, "a number" of the nanoAnalyzer 1000 systems have been placed with early access users, Erik Holmlin, the president and CEO of BioNanomatrix, said. "The Series B financing comes at a pivotal time for the company, as we advance toward commercialization" of the platform, he said in a statement.

BioNanomatrix was founded in 2003 and licensed its core technology from Princeton University.

Brian Halak, a partner at Domain Associates, is joining BioNanomatrix's board. He said that the funds will allow the company to establish a "strong West Coast presence that will provide additional business opportunities and the ability to recruit from a talent base that has established this industry."

The company did not disclose other uses of the funds.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.